The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2022
Filed:
Sep. 05, 2018
Applicant:
Lemonex Inc., Seoul, KR;
Inventors:
Dal-Hee Min, Seoul, KR;
Cheolhee Won, Seoul, KR;
Sejin Park, Seoul, KR;
Seongchan Kim, Gwangju-si, KR;
Assignee:
LEMONEX INC., Seoul, KR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C01B 37/02 (2006.01); C12N 5/00 (2006.01); A61K 9/50 (2006.01); B01J 13/02 (2006.01); B82Y 5/00 (2011.01); A61K 9/51 (2006.01); C12N 5/077 (2010.01); A61K 31/711 (2006.01); A61K 45/06 (2006.01); A61K 31/352 (2006.01); A61K 47/69 (2017.01); A61K 31/196 (2006.01); C12N 5/079 (2010.01); A61K 31/706 (2006.01); A61K 31/437 (2006.01); C12N 5/071 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C01B 37/02 (2013.01); A61K 9/501 (2013.01); A61K 9/5115 (2013.01); A61K 9/5192 (2013.01); A61K 31/196 (2013.01); A61K 31/352 (2013.01); A61K 31/437 (2013.01); A61K 31/706 (2013.01); A61K 31/711 (2013.01); A61K 45/06 (2013.01); A61K 47/6923 (2017.08); B01J 13/02 (2013.01); B82Y 5/00 (2013.01); C12N 5/0068 (2013.01); C12N 5/0618 (2013.01); C12N 5/0657 (2013.01); C12N 5/0678 (2013.01); A61K 2035/128 (2013.01); C12N 2501/385 (2013.01); C12N 2513/00 (2013.01); C12N 2533/14 (2013.01); C12N 2535/00 (2013.01);
Abstract
A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.